Immunosuppressive treatments in acute myocardial infarction and stroke

Current Pharmaceutical Biotechnology

Volumn 13, Issue 1, 2012, Pages 59-67

  Raffaghello, Lizzia ^a   Bianchi, Giovanna ^a   Pistoia, Vito ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

Antibodies; Atherosclerosis; Immunosuppressive therapy; Inflammation; Myocardial infarction; Stroke; T cells

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; HEAT SHOCK PROTEIN 60; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 2; LENALIDOMIDE; METHOTREXATE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; OXIDIZED LOW DENSITY LIPOPROTEIN; RAPAMYCIN; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE HEART INFARCTION; ADAPTIVE IMMUNITY; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; BRAIN INFARCTION SIZE; CELL INFILTRATION; CELLULAR IMMUNITY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; HEART INFARCTION; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; ISCHEMIC HEART DISEASE; LEUKEMIA; LEUKOCYTE ADHERENCE; LYMPHOMA; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL TRANSPLANTATION; NEUROPROTECTION; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN PHOSPHORYLATION; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR; STEM CELL TRANSPLANTATION; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ATHEROSCLEROSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOCARDIAL INFARCTION; STROKE;

ANIMALIA; MURINAE;

EID: 84855846623     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112798868755     Document Type: Review

References (122)

1. Hansson, G.K.; Libby, P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol., 2006, 6, 508-519.
2. Jonasson, L.; Holm, J.; Skalli, O.; Bondjers, G.; Hansson, G.K. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis, 1986, 6, 131-138.
3. Hansson, G.K. Atherosclerosis--an immune disease: The Anitschkov Lecture 2007. Atherosclerosis, 2009, 202, 2-10.
4. Hansson, G.K.; Holm, J.; Jonasson, L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am. J. Pathol., 1989, 135, 169-175.
5. Bobryshev, Y.V.; Lord, R.S. S-100 positive cells in human arterial intima and in atherosclerotic lesions. Cardiovasc. Res., 1995, 29, 689-696.
6. Kovanen, P.T.; Kaartinen, M.; Paavonen, T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation, 1995, 92, 1084-1088.
7. Watanabe, T.; Hirata, M.; Yoshikawa, Y.; Nagafuchi, Y.; Toyoshima, H.; Watanabe, T. Role of macrophages in atherosclerosis. Sequential observations of cholesterol-induced rabbit aortic lesion by the immunoperoxidase technique using monoclonal antimacrophage antibody. Lab. Invest., 1985, 53, 80-90.
8. Gown, A.M.; Tsukada, T.; Ross, R. Human atherosclerosis. II. Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am. J. Pathol., 1986, 125, 191-207.
9. Stemme, S.; Faber, B.; Holm, J.; Wiklund, O.; Witztum, J.L.; Hansson, G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA, 1995, 92, 3893-3897.
10. Palinski, W.; Rosenfeld, M.E.; Yla-Herttuala, S.; Gurtner, G.C.; Socher, S.S.; Butler, S.W.; Parthasarathy, S.; Carew, T.E.; Steinberg, D.; Witztum, J.L. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA, 1989, 86, 1372-1376.
11. Andersson, J.; Libby, P.; Hansson, G.K. Adaptive immunity and atherosclerosis. Clin. Immunol., 2010, 134, 33-46.
12. Breslow, J.L. Mouse models of atherosclerosis. Science, 1996, 272, 685-688.
13. Ishibashi, S.; Brown, M.S.; Goldstein, J.L.; Gerard, R.D.; Hammer, R.E.; Herz, J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest., 1993, 92, 883-893.
14. Piedrahita, J.A.; Zhang, S.H.; Hagaman, J.R.; Oliver, P.M.; Maeda, N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. U S A., 1992, 89, 4471-4475.
15. Plump, A.S.; Smith, J.D.; Hayek, T.; Aalto-Setala, K.; Walsh, A.; Verstuyft, J.G.; Rubin, E.M.; Breslow, J.L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell, 1992, 71, 343-353.
16. Zhou, X.; Stemme, S.; Hansson, G.K. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am. J. Pathol., 1996, 149, 359-366.
17. Emeson, E.E.; Shen, M.L.; Bell, C.G.; Qureshi, A. Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am. J. Pathol., 1996, 149, 675-685.
18. Huber, S.A.; Sakkinen, P.; David, C.; Newell, M.K.; Tracy, R.P. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation, 2001, 103, 2610-2616.
19. Daugherty, A.; Pure, E.; Delfel-Butteiger, D.; Chen, S.; Leferovich, J.; Roselaar, S.E.; Rader, D.J. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/-mice. J. Clin. Invest. 1997, 100, 1575-1580.
20. Dansky, H.M.; Charlton, S.A.; Harper, M.M.; Smith, J.D. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc. Natl. Acad Sci. USA, 1997, 94, 4642-4646.
21. Reardon, C.A.; Blachowicz, L.; White, T.; Cabana, V.; Wang, Y.; Lukens, J.; Bluestone, J.; Getz, G.S. Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler Thromb. Vasc. Biol., 2001, 21, 1011-1016.
22. Zhou, X.; Nicoletti, A.; Elhage, R.; Hansson, G.K. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation, 2000, 102, 2919-2922.
23. Elhage, R.; Gourdy, P.; Brouchet, L.; Jawien, J.; Fouque, M.J.; Fievet, C.; Huc, X.; Barreira, Y.; Couloumiers, J.C.; Arnal, J.F.; Bayard, F. Deleting TCR alpha beta+ or CD4+ T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-deficient mice. Am. J. Pathol., 2004, 165, 2013-2018.
24. Ludewig, B.; Freigang, S.; Jaggi, M.; Kurrer, M.O.; Pei, Y.C.; Vlk, L.; Odermatt, B.; Zinkernagel, R.M.; Hengartner, H. Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. Proc. Natl. Acad. Sci. U S A., 2000, 97, 12752-12757.
25. Henderson, E.L.; Geng, Y.J.; Sukhova, G.K.; Whittemore, A.D.; Knox, J.; Libby, P. Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms. Circulation, 1999, 99, 96-104.
26. Hansson, G.K.; Jonasson, L.; Seifert, P.S.; Stemme, S. Immune mechanisms in atherosclerosis. Arteriosclerosis, 1989, 9, 567-578.
27. Frostegard, J.; Ulfgren, A.K.; Nyberg, P.; Hedin, U.; Swedenborg, J.; Andersson, U.; Hansson, G.K. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis, 1999, 145, 33-43.
28. Uyemura, K.; Demer, L.L.; Castle, S.C.; Jullien, D.; Berliner, J.A.; Gately, M.K.; Warrier, R.R.; Pham, N.; Fogelman, A.M.; Modlin, R.L. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J. Clin. Invest., 1996, 97, 2130-2138.
29. Mallat, Z.; Besnard, S.; Duriez, M.; Deleuze, V.; Emmanuel, F.; Bureau, M.F.; Soubrier, F.; Esposito, B.; Duez, H.; Fievet, C.; Staels, B.; Duverger, N.; Scherman, D.; Tedgui, A. Protective role of interleukin-10 in atherosclerosis. Circ. Res., 1999, 85, e17-24.
30. Gupta, S.; Pablo, A.M.; Jiang, X.; Wang, N.; Tall, A.R.; Schindler, C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest., 1997, 99, 2752-2761.
31. Buono, C.; Come, C.E.; Stavrakis, G.; Maguire, G.F.; Connelly, P.W.; Lichtman, A.H. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb. Vasc. Biol., 2003, 23, 454-460.
32. Branen, L.; Hovgaard, L.; Nitulescu, M.; Bengtsson, E.; Nilsson, J.; Jovinge, S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb. Vasc. Biol., 2004, 24, 2137-2142.
33. Friesel, R.; Komoriya, A.; Maciag, T. Inhibition of endothelial cell proliferation by gamma-interferon. J. Cell Biol., 1987, 104, 689-696.
34. Hansson, G.K.; Hellstrand, M.; Rymo, L.; Rubbia, L.; Gabbiani, G. Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J. Exp. Med., 1989, 170, 1595-1608.
35. Amento, E.P.; Ehsani, N.; Palmer, H.; Libby, P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb, 1991, 11, 1223-1230.
36. van Hinsbergh, V.W.; van den Berg, E.A.; Fiers, W.; Dooijewaard, G. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood, 1990, 75, 1991-1998.
37. Lee, E.; Vaughan, D.E.; Parikh, S.H.; Grodzinsky, A.J.; Libby, P.; Lark, M.W.; Lee, R.T. Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. Circ. Res., 1996, 78, 44-49.
38. Saren, P.; Welgus, H.G.; Kovanen, P.T. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J. Immunol., 1996, 157, 4159-4165.
39. Davenport, P.; Tipping, P.G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein Edeficient mice. Am. J. Pathol., 2003, 163, 1117-1125.
40. King, V.L.; Szilvassy, S.J.; Daugherty, A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/-mice. Arterioscler Thromb Vasc. Biol., 2002, 22, 456-461.
41. Leskinen, M.J.; Kovanen, P.T.; Lindstedt, K.A. Regulation of smooth muscle cell growth, function and death in vitro by activated mast cells--a potential mechanism for the weakening and rupture of atherosclerotic plaques. Biochem Pharmacol., 2003, 66, 1493-1498.
42. Horkko, S.; Bird, D.A.; Miller, E.; Itabe, H.; Leitinger, N.; Subbanagounder, G.; Berliner, J.A.; Friedman, P.; Dennis, E.A.; Curtiss, L.K.; Palinski, W.; Witztum, J.L. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipidprotein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest., 1999, 103, 117-128.
43. Ait-Oufella, H.; Salomon, B.L.; Potteaux, S.; Robertson, A.K.; Gourdy, P.; Zoll, J.; Merval, R.; Esposito, B.; Cohen, J.L.; Fisson, S.; Flavell, R.A.; Hansson, G.K.; Klatzmann, D.; Tedgui, A.; Mallat, Z. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med., 2006, 12, 178-180.
44. Eid, R.E.; Rao, D.A.; Zhou, J.; Lo, S.F.; Ranjbaran, H.; Gallo, A.; Sokol, S.I.; Pfau, S.; Pober, J.S.; Tellides, G. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation, 2009, 119, 1424-1432.
45. Taleb, S.; Tedgui, A.; Mallat, Z. Regulatory T-cell immunity and its relevance to atherosclerosis. J. Intern. Med., 2008, 263, 489-499.
46. Salonen, J.T.; Yla-Herttuala, S.; Yamamoto, R.; Butler, S.; Korpela, H.; Salonen, R.; Nyyssonen, K.; Palinski, W.; Witztum, J.L. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet, 1992, 339, 883-887.
47. Ameli, S.; Hultgardh-Nilsson, A.; Regnstrom, J.; Calara, F.; Yano, J.; Cercek, B.; Shah, P.K.; Nilsson, J. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb. Vasc. Biol., 1996, 16, 1074-1079.
48. Maron, R.; Sukhova, G.; Faria, A.M.; Hoffmann, E.; Mach, F.; Libby, P.; Weiner, H.L. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation, 2002, 106, 1708-1715.
49. Emadi, A.; Jones, R.J.; Brodsky, R.A. Cyclophosphamide and cancer: golden anniversary. Nat. Rev. Clin. Oncol., 2009, 6, 638-647.
50. Lake, R.A.; Robinson, B.W. Immunotherapy and chemotherapy--a practical partnership. Nat. Rev. Cancer. 2005, 5, 397-405.
51. Bass, K.K.; Mastrangelo, M.J. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol. Immunother, 1998, 47, 1-12.
52. Tong, Y.; Song, W.; Crystal, R.G. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res., 2001, 61, 7530-7535.
53. Schiavoni, G.; Mattei, F.; Di Pucchio, T.; Santini, S.M.; Bracci, L.; Belardelli, F.; Proietti, E. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood, 2000, 95, 2024-2030.
54. Matar, P.; Rozados, V.R.; Gervasoni, S.I.; Scharovsky, O.G. Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response. Int. Immunopharmacol., 2001, 1, 307-319.
55. Ghiringhelli, F.; Larmonier, N.; Schmitt, E.; Parcellier, A.; Cathelin, D.; Garrido, C.; Chauffert, B.; Solary, E.; Bonnotte, B.; Martin, F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol., 2004, 34, 336-344.
56. Lutsiak, M.E.; Semnani, R.T.; De Pascalis, R.; Kashmiri, S.V.; Schlom, J.; Sabzevari, H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood, 2005, 105, 2862-2868.
57. Glaser, M. Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice. J. Exp. Med., 1979, 149, 774-779.
58. Chabner, B.A.; Roberts, T.G., Jr. Timeline: Chemotherapy and the war on cancer. Nat. Rev. Cancer, 2005, 5, 65-72.
59. Perry, M.C. The chemotherapy sourcebook William & Wilkins: Baltimore, 1992.
60. Liu, J.; Farmer, J.D., Jr.; Lane, W.S.; Friedman, J.; Weissman, I.; Schreiber, S.L. Calcineurin is a common target of cyclophilincyclosporin A and FKBP-FK506 complexes. Cell, 1991, 66, 807-815.
61. Fruman, D.A.; Burakoff, S.J.; Bierer, B.E. Immunophilins in protein folding and immunosuppression. FASEB J., 1994, 8, 391-400.
62. Shibasaki, F.; Kondo, E.; Akagi, T.; McKeon, F. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature, 1997, 386, 728-731.
63. Steiner, J.P.; Dawson, T.M.; Fotuhi, M.; Glatt, C.E.; Snowman, A.M.; Cohen, N.; Snyder, S.H. High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature, 1992, 358, 584-587.
64. Clipstone, N.A.; Crabtree, G.R. Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506. Ann. N. Y. Acad. Sci., 1993, 696, 20-30.
65. Sharkey, J.; Butcher, S.P. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature, 1994, 371, 336-339.
66. Yagita, Y.; Kitagawa, K.; Matsushita, K.; Taguchi, A.; Mabuchi, T.; Ohtsuki, T.; Yanagihara, T.; Matsumoto, M. Effect of immunosuppressant FK506 on ischemia-induced degeneration of hippocampal neurons in gerbils. Life Sci., 1996, 59, 1643-1650.
67. Bochelen, D.; Rudin, M.; Sauter, A. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J. Pharmacol Exp. Ther., 1999, 288, 653-659.
68. Furuichi, Y.; Katsuta, K.; Maeda, M.; Ueyama, N.; Moriguchi, A.; Matsuoka, N.; Goto, T.; Yanagihara, T. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res., 2003, 965, 137-145.
69. Furuichi, Y.; Maeda, M.; Moriguchi, A.; Sawamoto, T.; Kawamura, A.; Matsuoka, N.; Mutoh, S.; Yanagihara, T. Tacrolimus, a potential neuroprotective agent, ameliorates ischemic brain damage and neurologic deficits after focal cerebral ischemia in nonhuman primates. J. Cereb. Blood Flow Metab., 2003, 23, 1183-1194.
70. Atoui, R.; Shum-Tim, D.; Chiu, R.C. Myocardial regenerative therapy: immunologic basis for the potential "universal donor cells". Ann. Thorac. Surg., 2008, 86, 327-334.
71. Orlic, D.; Kajstura, J.; Chimenti, S.; Jakoniuk, I.; Anderson, S.M.; Li, B.; Pickel, J.; McKay, R.; Nadal-Ginard, B.; Bodine, D.M.; Leri, A.; Anversa, P. Bone marrow cells regenerate infarcted myocardium. Nature, 2001, 410, 701-705.
72. Davani, S.; Marandin, A.; Mersin, N.; Royer, B.; Kantelip, B.; Herve, P.; Etievent, J.P.; Kantelip, J.P. Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. Circ. Supp. 1, 2003, 108, II253-258.
73. Atoui, R.; Asenjo, J.F.; Duong, M.; Chen, G.; Chiu, R.C.; Shum-Tim, D. Marrow stromal cells as universal donor cells for myocardial regenerative therapy: their unique immune tolerance. Ann. Thorac. Surg., 2008, 85, 571-579.
74. Dai, W.; Hale, S.L.; Martin, B.J.; Kuang, J.Q.; Dow, J.S.; Wold, L.E.; Kloner, R.A. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short-and long-term effects. Circulation, 2005, 112, 214-223.
75. Saito, T.; Kuang, J.Q.; Lin, C.C.; Chiu, R.C. Transcoronary implantation of bone marrow stromal cells ameliorates cardiac function after myocardial infarction. J. Thorac. Cardiovasc. Surg., 2003, 126, 114-123.
76. Tomita, S.; Li, R.K.; Weisel, R.D.; Mickle, D.A.; Kim, E.J.; Sakai, T.; Jia, Z.Q. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation, 1999, 100, II247-256.
77. Uccelli, A.; Moretta, L.; Pistoia, V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol., 2008, 8, 726-736.
78. Schachinger, V.; Erbs, S.; Elsasser, A.; Haberbosch, W.; Hambrecht, R.; Holschermann, H.; Yu, J.; Corti, R.; Mathey, D.G.; Hamm, C.W.; Suselbeck, T.; Assmus, B.; Tonn, T.; Dimmeler, S.; Zeiher, A.M. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med., 2006, 355, 1210-1221.
79. Squadrito, F.; Altavilla, D.; Squadrito, G.; Saitta, A.; Campo, G.M.; Arlotta, M.; Quartarone, C.; Ferlito, M.; Caputi, A.P. Cyclosporin-A reduces leukocyte accumulation and protects against myocardial ischaemia reperfusion injury in rats. Eur. J. Pharmacol., 1999, 364, 159-168.
80. Squadrito, F.; Saitta, A.; Altavilla, D.; Ioculano, M.; Canale, P.; Campo, G.M.; Squadrito, G.; Di Tano, G.; Mazzu, A.; Caputi, A.P. Thrombolytic therapy with urokinase reduces increased circulating endothelial adhesion molecules in acute myocardial infarction. Inflamm. Res., 1996, 45, 14-19.
81. Squadrito, F.; Altavilla, D.; Zingarelli, B.; Ioculano, M.; Calapai, G.; Campo, G.M.; Miceli, A.; Prosdocimi, M.; Caputi, A.P. The effect of cloricromene, a coumarine derivative, on leukocyte accumulation, myocardial necrosis and TNF-alpha production in myocardial ischaemia-reperfusion injury. Life Sci., 1993, 53, 341-355.
82. Kwak, B.; Mulhaupt, F.; Myit, S.; Mach, F. Statins as a newly recognized type of immunomodulator. Nat Med., 2000, 6, 1399-1402.
83. Mach, F. Statins as immunomodulators. Transpl. Immunol., 2002, 9, 197-200.
84. Lee, S.J.; Qin, H.; Benveniste, E.N. Simvastatin inhibits IFNgamma-induced CD40 gene expression by suppressing STAT-1alpha. J. Leukoc. Biol., 2007, 82, 436-447.
85. Townsend, K.P.; Shytle, D.R.; Bai, Y.; San, N.; Zeng, J.; Freeman, M.; Mori, T.; Fernandez, F.; Morgan, D.; Sanberg, P.; Tan, J. Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J. Neurosci. Res., 2004, 78, 167-176.
86. Youssef, S.; Stuve, O.; Patarroyo, J.C.; Ruiz, P.J.; Radosevich, J.L.; Hur, E.M.; Bravo, M.; Mitchell, D.J.; Sobel, R.A.; Steinman, L.; Zamvil, S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature, 2002, 420, 78-84.
87. Yilmaz, A.; Reiss, C.; Tantawi, O.; Weng, A.; Stumpf, C.; Raaz, D.; Ludwig, J.; Berger, T.; Steinkasserer, A.; Daniel, W.G.; Garlichs, C.D. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis, 2004, 172, 85-93.
88. Hillyard, D.Z.; Cameron, A.J.; McIntyre, A.H.; Hadden, M.H.; Marshall, H.E.; Johnston, N.; Jardine, A.G. Inhibition of proliferation and signalling mechanisms in human lymphocytes by fluvastatin. Clin. Exp. Pharmacol. Physiol., 2002, 29, 673-678.
89. Azuma, R.W.; Suzuki, J.; Ogawa, M.; Futamatsu, H.; Koga, N.; Onai, Y.; Kosuge, H.; Isobe, M. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovasc. Res., 2004, 64, 412-420.
90. Waiczies, S.; Prozorovski, T.; Infante-Duarte, C.; Hahner, A.; Aktas, O.; Ullrich, O.; Zipp, F. Atorvastatin induces T cell anergy via phosphorylation of ERK1. J. Immunol., 2005, 174, 5630-5635.
91. Coward, W.; Chow, S.C. Effect of atorvastatin on TH1 and TH2 cytokine secreting cells during T cell activation and differentiation. Atherosclerosis, 2006, 186, 302-309.
92. Weitz-Schmidt, G.; Welzenbach, K.; Brinkmann, V.; Kamata, T.; Kallen, J.; Bruns, C.; Cottens, S.; Takada, Y.; Hommel, U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med., 2001, 7, 687-692.
93. Massy, Z.A.; Keane, W.F.; Kasiske, B.L. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet, 1996, 347, 102-103.
94. Mausner-Fainberg, K.; Luboshits, G.; Mor, A.; Maysel-Auslender, S.; Rubinstein, A.; Keren, G.; George, J. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis, 2008, 197, 829-839.
95. Montecucco, F.; Burger, F.; Pelli, G.; Poku, N.K.; Berlier, C.; Steffens, S.; Mach, F. Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology (Oxford), 2009, 48, 233-242.
96. Offner, H.; Vandenbark, A.A.; Hurn, P.D. Effect of experimental stroke on peripheral immunity: CNS ischemia induces profound immunosuppression. Neuroscience, 2009, 158, 1098-1111.
97. Lo, E.H. T time in the brain. Nat. Med., 2009, 15, 844-846.
98. Li, J.Y.; Furuichi, Y.; Matsuoka, N.; Mutoh, S.; Yanagihara, T. Tacrolimus (FK506) attenuates biphasic cytochrome c release and Bad phosphorylation following transient cerebral ischemia in mice. Neuroscience, 2006, 142, 789-797.
99. Kaminska, B.; Gaweda-Walerych, K.; Zawadzka, M. Molecular mechanisms of neuroprotective action of immunosuppressants--facts and hypotheses. J. Cell Mol. Med., 2004, 8, 45-58.
100. Brecht, S.; Waetzig, V.; Hidding, U.; Hanisch, U.K.; Walther, M.; Herdegen, T.; Neiss, W.F. FK506 protects against various immune responses and secondary degeneration following cerebral ischemia. Anat. Rec. (Hoboken), 2009, 292, 1993-2001.
101. Miljan, E.A.; Sinden, J.D. Stem cell treatment of ischemic brain injury. Curr. Opin. Mol. Ther., 2009, 11, 394-403.
102. Liu, Y.P.; Lang, B.T.; Baskaya, M.K.; Dempsey, R.J.; Vemuganti, R. The potential of neural stem cells to repair stroke-induced brain damage. Acta Neuropathol., 2009, 117, 469-480.
103. Dharmasaroja, P. Bone marrow-derived mesenchymal stem cells for the treatment of ischemic stroke. J. Clin. Neurosci., 2009, 16, 12-20.
104. Yu, G.; Borlongan, C.V.; Stahl, C.E.; Hess, D.C.; Ou, Y.; Kaneko, Y.; Yu, S.J.; Yang, T.; Fang, L.; Xie, X. Systemic delivery of umbilical cord blood cells for stroke therapy: a review. Restor. Neurol. Neurosci., 2009, 27, 41-54.
105. Wang, L.; Shi, J.; van Ginkel, F.W.; Lan, L.; Niemeyer, G.; Martin, D.R.; Snyder, E.Y.; Cox, N.R. Neural stem/progenitor cells modulate immune responses by suppressing T lymphocytes with nitric oxide and prostaglandin E2. Exp. Neurol., 2009, 216, 177-183.
106. Akesson, E.; Wolmer-Solberg, N.; Cederarv, M.; Falci, S.; Odeberg, J. Human neural stem cells and astrocytes, but not neurons, suppress an allogeneic lymphocyte response. Stem. Cell Res., 2009, 2, 56-67.
107. Fainstein, N.; Vaknin, I.; Einstein, O.; Zisman, P.; Ben Sasson, S.Z.; Baniyash, M.; Ben-Hur, T. Neural precursor cells inhibit multiple inflammatory signals. Mol. Cell Neurosci., 2008, 39, 335-341.
108. Keimpema, E.; Fokkens, M.R.; Nagy, Z.; Agoston, V.; Luiten, P.G.; Nyakas, C.; Boddeke, H.W.; Copray, J.C. Early transient presence of implanted bone marrow stem cells reduces lesion size after cerebral ischaemia in adult rats. Neuropathol. Appl. Neurobiol., 2009, 35, 89-102.
109. Chen, S.H.; Chang, F.M.; Tsai, Y.C.; Huang, K.F.; Lin, C.L.; Lin, M.T. Infusion of human umbilical cord blood cells protect against cerebral ischemia and damage during heatstroke in the rat. Exp. Neurol., 2006, 199, 67-76.
110. Vendrame, M.; Gemma, C.; de Mesquita, D.; Collier, L.; Bickford, P.C.; Sanberg, C.D.; Sanberg, P.R.; Pennypacker, K.R.; Willing, A.E. Anti-inflammatory effects of human cord blood cells in a rat model of stroke. Stem. Cells Dev., 2005, 14, 595-604.
111. Shen, Q.; Goderie, S.K.; Jin, L.; Karanth, N.; Sun, Y.; Abramova, N.; Vincent, P.; Pumiglia, K.; Temple, S. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science, 2004, 304, 1338-1340.
112. Lin, N.; Friedlander, R.M. T-cell activation in ischemic stroke: a new therapeutic target for delayed infarct expansion? Neurosurgery, 2009, 65, N13.
113. Shichita, T.; Sugiyama, Y.; Ooboshi, H.; Sugimori, H.; Nakagawa, R.; Takada, I.; Iwaki, T.; Okada, Y.; Iida, M.; Cua, D.J.; Iwakura, Y.; Yoshimura, A. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat. Med., 2009, 15, 946-950.
114. Tweedie, D.; Luo, W.; Short, R.G.; Brossi, A.; Holloway, H.W.; Li, Y.; Yu, Q.S.; Greig, N.H. A cellular model of inflammation for identifying TNF-alpha synthesis inhibitors. J. Neurosci. Methods, 2009, 183, 182-187.
115. Tobinick, E. Perispinal etanercept for treatment of Alzheimer's disease. Curr. Alzheimer Res., 2007, 4, 550-552.
116. Tobinick, E. Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Medscape J. Med., 2008, 10, 135.
117. Tobinick, E. Perispinal etanercept for neuroinflammatory disorders. Drug Discov. Today, 2009, 14, 168-177.
118. Moreira, A.L.; Sampaio, E.P.; Zmuidzinas, A.; Frindt, P.; Smith, K.A.; Kaplan, G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med., 1993, 177, 1675-1680.
119. Melchert, M.; List, A. The thalidomide saga. Int. J. Biochem. Cell Biol., 2007, 39, 1489-1499.
120. Ocio, E.M.; Mateos, M.V.; Maiso, P.; Pandiella, A.; San-Miguel, J.F. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol., 2008, 9, 1157-1165.
121. Connell, W.R.; Kamm, M.A.; Dickson, M.; Balkwill, A.M.; Ritchie, J.K.; Lennard-Jones, J.E. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet, 1994, 343, 1249-1252.
122. Stone, G.W.; Rizvi, A.; Newman, W.; Mastali, K.; Wang, J.C.; Caputo, R.; Doostzadeh, J.; Cao, S.; Simonton, C.A.; Sudhir, K.; Lansky, A.J.; Cutlip, D.E.; Kereiakes, D.J. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N. Engl. J. Med., 362, 1663-1674.